Mounjaro (tirzepatide), Eli Lilly’s Type 2 diabetes drug, helped obese and overweight adults lose an average of 64 pounds after 84 weeks in a phase 3 trial. The study involved more than 800 patients who have weight-related comorbidities not related to Type 2 diabetes. For 12 weeks, the participants engaged in an “intensive lifestyle intervention” […]
